Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152541 | 0.86 | NPC1 (0.34) | NPC1SMYD2DGAT1F11KDM4E | |
| SCHEMBL14151672 | 0.82 | NPC1 (0.35) | NPC1SMYD2DGAT1F11 | |
| SCHEMBL14152358 | 0.80 | DGAT1 (0.36) | NPC1SMYD2DGAT1 | |
| SCHEMBL14151421 | 0.76 | DGAT1 (0.34) | SMYD2DGAT1 | |
| SCHEMBL14152185 | 0.75 | NPC1 (0.34) | NPC1 | |
| SCHEMBL25712859 | 0.74 | DGAT1 (0.32) | NPC1SMYD2DGAT1 | |
| SCHEMBL2827211 | 0.73 | MAPT (0.30) | DGAT1 | |
| SCHEMBL14152168 | 0.72 | NPC1 (0.34) | NPC1DGAT1F11KDM4EHSD17B10 | |
| SCHEMBL14152329 | 0.72 | NPC1 (0.30) | NPC1SMYD2 | |
| SCHEMBL14152327 | 0.72 | NPC1 (0.30) | NPC1SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2537831-B1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-12-03 | — | — | EP | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653126-B2 | Imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-18 | — | — | US | disclosed |
| EP-2537831-A1 | IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
| US-20120316170-A1 | Imidazole Derivative | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316170-A1 | Imidazole Derivative | S1PR2, S1PR1, SPHK2 | NPC1 149/4885SMYD2 1015/4885DGAT1 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.